SORBITOL-MANNITOL
Clinical safety rating: safe
Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
Sorbitol and mannitol are sugar alcohols that act as osmotic diuretics. They are filtered by the glomerulus but not reabsorbed, increasing osmotic pressure in the tubular lumen, thereby reducing water reabsorption and promoting diuresis. They also increase intraocular pressure and decrease intracranial pressure by drawing water from tissues into the bloodstream.
| Metabolism | Both sorbitol and mannitol are not metabolized to a significant extent. They are primarily excreted unchanged by the kidney. Minor metabolism of sorbitol to fructose in the liver may occur. |
| Excretion | Primarily renal excretion as unchanged drug; >90% eliminated via urine within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours; may be prolonged in renal impairment. |
| Protein binding | Not significantly protein bound (<5%). |
| Volume of Distribution | Vd approximately 0.3-0.5 L/kg; distributes primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is low (approximately 10-20%) due to poor absorption; intravenously, bioavailability is 100%. |
| Onset of Action | Intravenous administration: osmotic diuresis begins within 1-3 hours after infusion; oral administration: cathartic effect occurs within 0.5-3 hours. |
| Duration of Action | Intravenous: diuretic effect lasts 4-6 hours; oral: cathartic effect lasts 3-6 hours. |
Osmotic diuretic; 50-100 g (as 25% solution) IV over 30-60 minutes, may repeat every 6-12 hours as needed; maximum 200 g/day.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in anuria and severe renal impairment (GFR < 20 mL/min). Use with caution if GFR 20-50 mL/min, reduce dose by 50% and monitor serum osmolality. |
| Liver impairment | No specific adjustment required; use with caution in severe hepatic impairment due to risk of volume overload and electrolyte disturbances. |
| Pediatric use | 0.5-2 g/kg (as 25% solution) IV over 30-60 minutes, may repeat every 6-12 hours; maximum 2 g/kg per dose. |
| Geriatric use | Start at lowest effective dose (25-50 g) and titrate; monitor renal function, electrolytes, and volume status closely due to increased risk of renal impairment and fluid overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
| FDA category | Animal |
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Low oral bioavailability suggests minimal infant exposure from maternal ingestion; intravenous administration may result in low levels. Caution advised; consider waiting 4 hours after infusion before breastfeeding to minimize exposure. Probably compatible with breastfeeding with monitoring. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | edema |
| Serious Effects |
["Anuria or severe renal failure (contraindicates osmotic diuresis)","Pulmonary edema or congestive heart failure","Intracranial hemorrhage (mannitol)","Hypersensitivity to sorbitol or mannitol","Dehydration or hypovolemia"]
| Precautions | ["Monitor serum electrolytes and renal function; risk of hypernatremia or hyponatremia","May worsen heart failure due to increased intravascular volume","Use caution in patients with severe renal impairment or anuria","Intravenous administration of mannitol can cause crystalluria","Sorbitol in dialysis solutions may cause hyperglycemia in diabetic patients"] |
Loading safety data…
| Sorbitol and mannitol are hexahydric alcohols used as osmotic diuretics. Limited human data; animal studies show no teratogenicity at therapeutic doses. Inadvertent intravenous use in pregnancy may cause maternal electrolyte imbalance, dehydration, and potential fetal compromise from altered placental perfusion. First trimester: no established teratogenic risk. Second and third trimesters: risk of maternal hypotension and fetal hypoxia if rapid administration; avoid unless clearly needed. Consider alternative agents if risk-benefit justified. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, serum electrolytes, osmolality, and fluid balance before, during, and after administration. Fetal heart rate monitoring during infusion if viable pregnancy. Urine output assessment to avoid over-diuresis. Signs of pulmonary edema or congestive heart failure in mother. |
| Fertility Effects | No known negative impact on human fertility. Animal studies show no adverse effects on reproduction. However, chronic use in conditions like glaucoma (sorbitol) may be theoretical but no established clinical effect. |